Abstract
The fluoroquinolones are a commonly prescribed class of antibiotics with broad activity across a variety of bacteria. As an antimicrobial class, the fluoroquinolones exert antimicrobial activity by direct inhibition of DNA synthesis due to interaction between the fluoroquinolone and two enzymes essential for DNA replication: DNA gyrase and DNA topoisomerase IV. Adverse events and widespread antimicrobial resistance remain two of the major concerns regarding fluoroquinolone use. Resistance can emerge following target site mutations, reduced influx, efflux, target protection, and enzymatic modification of the fluoroquinolones. Recent developments for the fluoroquinolones include revision of susceptibility test breakpoints for Enterobacterales and Pseudomonas aeruginosa, as well as approval of a novel fluoroquinolone, delafloxacin. This review provides an overview of the fluoroquinolones and resistance mechanisms and describes recent developments in susceptibility testing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
